Dr. Rule on Potential for CAR T-Cell Therapy in MCL


Simon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma (MCL).

Data on using CAR T-cell therapy to treat patients with MCL will be presented at the 2019 ASH Annual Meeting. Rule is hoping CAR T-cell therapy will be a contributing treatment and believes it will work best post-BTK inhibitor.

CAR T-cell therapy may even have the potential to replace allogeneic stem cell transplant, according to Rule. This would be a positive advance because many physicians do not like the toxicity associated with allogeneic stem cell transplant, particularly graft-versus-host disease. However, long-term data are necessary before CAR T-cell therapy is used in place of allogeneic stem cell transplant, concludes Rule.

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.